Topics

Companies Related to "study targets Achilles heel pancreatic cancer with promising" [Most Relevant Company Matches] RSS

12:26 EDT 22nd July 2019 | BioPortfolio

Here are the most relevant search results for "study targets Achilles heel pancreatic cancer with promising" found in our extensive corporate database of over 50,000 company records.

Showing "study targets Achilles heel pancreatic cancer with promising" Companies 1–25 of 3,600+

Extremely Relevant

World Pancreatic Cancer Coalition

The World Pancreatic Cancer Coalition is an international group of pancreatic cancer patient advocacy groups with a mission to drive transformational change for all those affected by the disease. Through global collaboration, the coalition raises awareness of pancreatic cancer by strengthening the efforts of participating member organizations. Each Novembe...


Pancreatic Cancer Action

About Pancreatic Cancer Action: 5 year survival rates for pancreatic cancer have not changed in over 40 years and it is our mission to change this by way of increased awareness of pancreatic cancer within the general population, the medical community and the Government. We are developing educational programmes for trainee General Practitioners and are working on creating free Online Interactive...

Relevant

Sky Foundation, Inc.

After being diagnosed with pancreatic cancer in 2007 and responding well to treatment, Kasselman established Sky Foundation to fund research for the Sky Foundation Pancreatic Cancer Research Fund at the Barbara Ann Karmanos Cancer Institute to develop a diagnostic tool for the early detection of pancreatic cancer.


Pancreatic Cancer Action Network

The Pancreatic Cancer Action Network is the only national organization creating hope in a comprehensive way through research, patient support, community outreach and advocacy for a cure. The organization raises money for direct private funding of research -- and advocates for more aggressive federal research funding of medical breakthroughs in prevention, diagnosis and treatment of pancreatic canc...

Agensys

Agensys, Inc. is developing a pipeline of therapeutic fully human monoclonal antibodies (MAbs) to treat solid tumor cancers based on its own proprietary targets. The Company has discovered and validated a rich portfolio of novel, clinically relevant cancer targets to 14 different cancer types that have been carefully selected to enable development of new effective therapeutics with fewer and less ...

The Lustgarten Foundation

The Lustgarten Foundation, based in Bethpage, New York, is America's largest private foundation dedicated solely to funding pancreatic cancer research. Founded in 1998, the Foundation provides critical support in the search for better diagnostics and treatment of pancreatic cancer, and to date has provided more than $32 million to more than 115 research projects at 41 medical and research centers ...

The Belfer Institute for Applied Cancer Science

The Belfer Institute for Applied Cancer Science at Dana-Farber Cancer Institute is a fully integrated, collaborative cancer research center offering innovative drug discovery capabilities that range from the identification of cancer-causing genetic mutations to the full validation and selection of new drug targets. This unique approach enables the Institut...

Biologische Heilmittel Heel GmbH

We build the bridge between homeopathy and conventional medicine.We achieve the vision of our company founder with passion and expertise, making Heel the global leader in the field of scientifically-based modern homeopathy as an integral part of medicine.Our medications are easy to use and gently activate the body’s self-healing powers - as intended by nature and requested by health care profess...

The Finnish Breast Cancer Group

The study, led by the Finnish Breast Cancer Group, was a large open-label, two-arm, randomised multicentre phase III study in women with early breast cancer. 1,500 patients in Finland and Sweden with no distant metastases who had an intermediate to high risk of recurrence within five years from the time of diagnosis, were recruited to the study.

Kenner Family Research Fund

Kenner Family Research Fund (KFRF) was formed by family and friends of Peter Kenner, who died shortly after his diagnosis of neuroendocrine pancreatic cancer. KFRF (a fund of JCF, a registered 501(c)3 organization) is committed to the development of an early detection protocol for pancreatic cancer that will be used by primary care physicians (www.kennerfa...

The Lustgarten Foundation for Pancreatic Cancer Research

Founded in 1998 by Cablevision executive Marc Lustgarten, with Cablevision chairman Charles Dolan and CEO James Dolan, The Lustgarten Foundation is the nation's largest private, non-profit supporter of pancreatic cancer research, providing more than $20 million to date. The Foundation provides patient information and manages a national public awareness campaign. To learn more and to see Dr. Pa...

Propanc Biopharma, Inc.

Propanc Biopharma, Inc. (the "Company") is a biopharmaceutical company developing new cancer treatments initially for patients suffering from pancreatic, ovarian and colorectal cancers. The Company has developed a formulation of anti-cancer compounds, which exert a number of effects designed to control or prevent tumors from recurring and spreading through...

Synergys Biotherapeutics

Synergys is an early stage company developing multifunctional anti-vascularization antibody drugs targeting VEGF-alternative pathways. The Company’s most advanced product candidate, Anti-EGFR‐TAP (SYN001) was derived from its platform technology termed A‐TAP (Antibody-Targeted Anti-Vascularization Payload). SYN001 is currently in preclinical ...

Siamab Therapeutics, Inc.

Siamab Therapeutics, Inc. is a biopharmaceutical company developing novel cancer immunotherapies targeting cancer-specific carbohydrate antigens seen in multiple solid tumors. Siamab has developed a platform that enables the rapid discovery and development of therapeutic antibodies that bind with unprecedented specificity and affinity to this novel class o...

PreScience Labs, LLC

PreScience is a developmental stage bio-pharmaceutical company focused on the development of anti-cancer drugs. It has successfully completed preclinical mechanistic, in vitro and animal testing using intra-arterial delivery of its proprietary drug PSL-001. The FDA approved immediate enrollment of a Phase I, dose-escalating study, which PreScience intends ...

Kronos Bio, Inc.

Kronos Bio is dedicated to the research and development of first-in-class therapies that modulate historically recalcitrant cancer targets. Leveraging industry-leading research into high-throughput screening strategies for chemical modulators of transcription factors and other challenging targets in oncology, Kronos utilizes its small molecule microarray (...

Tragara Pharmaceuticals

Tragara Pharmaceuticals, Inc. is a privately-held pharmaceutical company based in San Diego, Calif. The company is focused on the clinical and commercial development of proprietary medicines for the treatment of cancer and inflammation. Tragara's lead therapeutic program, Capoxigem® (apricoxib, TG01), is currently in Phase II clinical development in lung and pancreatic cancers and has completed...

AB Science SA

Founded in 2001, AB Science is a pharmaceutical company specialising in the research, development and commercialisation of protein kinase inhibitors (PKIs), a new class of targeted molecules whose action is to modify signalling pathways within cells. Through these PKIs, the Company targets diseases with high unmet medical needs (cancer, inflammatory diseas...

Tarveda Therapeutics®, Inc.

Tarveda Therapeutics is a clinical stage biopharmaceutical company that is developing and discovering a new class of potent and selective precision oncology medicines for the treatment of patients with solid tumor malignancies. We are developing our proprietary Pentarin® miniature conjugates to enhance the effectiveness of promising anti-cancer payloads...

AndroScience Corporation

Founded in 2000, AndroScience Corporation (ASC) is developing two novel small molecule platforms based on the therapeutic targets of the androgen receptor (AR) and select members of the Signal Transducer and Activator of Transcription (STAT) signaling pathway. The first patented family of compounds function through the enhancing degradation of AR protein, a novel mechanism of action described as A...

BioMarker Strategies

BioMarker Strategies (www.biomarkerstrategies.com) is a cancer diagnostics company that is developing a novel biomarker testing system to improve the treatment of cancer. SnapPath™ incorporates an automated and proprietary live-tumor-cell processing device with first-in-class, ex vivo biomarker tests to predict patient response to targeted cancer ther...

LifeSpan Biosciences

LifeSpan is the industry leader in molecular pathology. LifeSpan sells antibodies, immunohistochemistry services and localization databases. Founded in 1995, LifeSpan has developed proprietary antibodies to major classes of drug targets to study the expression of these proteins in normal and diseased human tissues.LifeSpan is also a leader in high-throughput imaging and cancer recognition software...

Active Biotech Research AB

Active Biotech focuses on developing pharmaceuticals for medical fields in which the immune system plays a central role.Our pharmaceutical development is based on our specialist know-how in the field of immunology. We possess a unique infrastructure that includes highly experienced researchers who combine cutting edge expertise with efficient project work focusing on clearly defined targets. Our p...

Nagourney Cancer Institute

The Nagourney Cancer Institute is a clinical research center that has pioneered the study of human tumor tissue for individualized cancer patient drug selection and has facilitated cancer drug discovery.

Pharmexa

Pharmexa is a leading biotech company in the field of active immunotherapy and vaccines for the treatment of cancer, serious chronic and infectious diseases. The company has been listed on the Copenhagen Stock Exchange since 2000. The Pharmexa group consists of GemVax AS, a Norwegian subsidiary, developing peptide vaccines for cancer and Pharmexa-Epimmune, a US subsidiary, focusing on T cell epito...


More From BioPortfolio on "study targets Achilles heel pancreatic cancer with promising"

Quick Search

Corporate Database Quicklinks